vs
ADMA BIOLOGICS, INC.（ADMA）とCOMSCORE, INC.（SCOR）の財務データ比較。上の社名をクリックして会社を切り替えられます
ADMA BIOLOGICS, INC.の直近四半期売上が大きい（$139.2M vs $93.5M、COMSCORE, INC.の約1.5倍）。ADMA BIOLOGICS, INC.の純利益率が高く（35.5% vs 3.2%、差は32.2%）。ADMA BIOLOGICS, INC.の前年同期比売上増加率が高い（18.4% vs -1.5%）。ADMA BIOLOGICS, INC.の直近四半期フリーキャッシュフローが多い（$34.6M vs $2.9M）。過去8四半期でADMA BIOLOGICS, INC.の売上複合成長率が高い（30.4% vs 3.8%）
ADMAバイオロジクス社は血漿由来の特殊免疫グロブリン療法の研究開発・製造・販売を専門とするバイオ医薬品企業で、主に米国市場で事業を展開しています。原発性免疫不全症やその他免疫関連疾患の患者、医療従事者、医療機関に免疫健康分野の治療ソリューションを提供しています。
Comscoreはアメリカ合衆国に本拠を置く世界的なメディア計測・分析企業で、企業、広告代理店、ブランドマーケター、出版社に対して専門的なマーケティングデータと分析サービスを提供しています。
ADMA vs SCOR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $139.2M | $93.5M |
| 純利益 | $49.4M | $3.0M |
| 粗利率 | 63.8% | 41.0% |
| 営業利益率 | 45.1% | 7.0% |
| 純利益率 | 35.5% | 3.2% |
| 売上前年比 | 18.4% | -1.5% |
| 純利益前年比 | -55.9% | -3.7% |
| EPS（希薄化後） | $0.20 | $9.50 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $139.2M | $93.5M | ||
| Q3 25 | $134.2M | $88.9M | ||
| Q2 25 | $122.0M | $89.4M | ||
| Q1 25 | $114.8M | $85.7M | ||
| Q4 24 | $117.5M | $94.9M | ||
| Q3 24 | $119.8M | $88.5M | ||
| Q2 24 | $107.2M | $85.8M | ||
| Q1 24 | $81.9M | $86.8M |
| Q4 25 | $49.4M | $3.0M | ||
| Q3 25 | $36.4M | $453.0K | ||
| Q2 25 | $34.2M | $-9.5M | ||
| Q1 25 | $26.9M | $-4.0M | ||
| Q4 24 | $111.9M | $3.1M | ||
| Q3 24 | $35.9M | $-60.6M | ||
| Q2 24 | $32.1M | $-1.7M | ||
| Q1 24 | $17.8M | $-1.1M |
| Q4 25 | 63.8% | 41.0% | ||
| Q3 25 | 56.3% | 40.6% | ||
| Q2 25 | 55.1% | 40.6% | ||
| Q1 25 | 53.2% | 39.6% | ||
| Q4 24 | 53.9% | 42.4% | ||
| Q3 24 | 49.8% | 41.2% | ||
| Q2 24 | 53.6% | 39.5% | ||
| Q1 24 | 47.8% | 42.3% |
| Q4 25 | 45.1% | 7.0% | ||
| Q3 25 | 38.0% | 1.9% | ||
| Q2 25 | 35.1% | -1.9% | ||
| Q1 25 | 30.4% | -2.4% | ||
| Q4 24 | 32.6% | 4.1% | ||
| Q3 24 | 33.1% | -67.4% | ||
| Q2 24 | 36.6% | -2.2% | ||
| Q1 24 | 26.7% | -2.2% |
| Q4 25 | 35.5% | 3.2% | ||
| Q3 25 | 27.1% | 0.5% | ||
| Q2 25 | 28.1% | -10.6% | ||
| Q1 25 | 23.4% | -4.7% | ||
| Q4 24 | 95.2% | 3.3% | ||
| Q3 24 | 30.0% | -68.5% | ||
| Q2 24 | 29.9% | -2.0% | ||
| Q1 24 | 21.7% | -1.2% |
| Q4 25 | $0.20 | $9.50 | ||
| Q3 25 | $0.15 | $-0.86 | ||
| Q2 25 | $0.14 | $-2.73 | ||
| Q1 25 | $0.11 | $-1.66 | ||
| Q4 24 | $0.45 | $-0.47 | ||
| Q3 24 | $0.15 | $-12.79 | ||
| Q2 24 | $0.13 | $-1.19 | ||
| Q1 24 | $0.08 | $-1.08 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $87.6M | $23.6M |
| 総負債低いほど良い | $72.1M | $41.5M |
| 株主資本純資産 | $477.3M | $111.4M |
| 総資産 | $624.2M | $407.7M |
| 負債/資本比率低いほどレバレッジが低い | 0.15× | 0.37× |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $87.6M | $23.6M | ||
| Q3 25 | $61.4M | $26.7M | ||
| Q2 25 | $90.3M | $26.0M | ||
| Q1 25 | $71.6M | $31.0M | ||
| Q4 24 | $103.1M | $29.9M | ||
| Q3 24 | $86.7M | $20.0M | ||
| Q2 24 | $88.2M | $14.7M | ||
| Q1 24 | $45.3M | $18.7M |
| Q4 25 | $72.1M | $41.5M | ||
| Q3 25 | $72.4M | $41.4M | ||
| Q2 25 | — | $41.3M | ||
| Q1 25 | — | $41.3M | ||
| Q4 24 | $72.3M | $41.2M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $477.3M | $111.4M | ||
| Q3 25 | $431.2M | $-26.3M | ||
| Q2 25 | $398.3M | $-21.7M | ||
| Q1 25 | $373.4M | $-13.5M | ||
| Q4 24 | $349.0M | $-8.3M | ||
| Q3 24 | $231.9M | $-2.7M | ||
| Q2 24 | $188.3M | $45.8M | ||
| Q1 24 | $153.7M | $51.4M |
| Q4 25 | $624.2M | $407.7M | ||
| Q3 25 | $568.7M | $406.9M | ||
| Q2 25 | $558.4M | $415.9M | ||
| Q1 25 | $510.6M | $421.5M | ||
| Q4 24 | $488.7M | $430.2M | ||
| Q3 24 | $390.6M | $412.5M | ||
| Q2 24 | $376.4M | $474.1M | ||
| Q1 24 | $350.9M | $477.7M |
| Q4 25 | 0.15× | 0.37× | ||
| Q3 25 | 0.17× | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.21× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $35.6M | $3.2M |
| フリーキャッシュフロー営業CF - 設備投資 | $34.6M | $2.9M |
| FCFマージンFCF / 売上 | 24.8% | 3.1% |
| 設備投資強度設備投資 / 売上 | 0.8% | 0.3% |
| キャッシュ転換率営業CF / 純利益 | 0.72× | 1.07× |
| 直近12ヶ月FCF直近4四半期 | $27.8M | $21.8M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $35.6M | $3.2M | ||
| Q3 25 | $13.3M | $9.5M | ||
| Q2 25 | $21.1M | $932.0K | ||
| Q1 25 | $-19.7M | $9.1M | ||
| Q4 24 | $50.2M | $-10.0M | ||
| Q3 24 | $25.0M | $12.5M | ||
| Q2 24 | $45.6M | $8.7M | ||
| Q1 24 | $-2.2M | $6.9M |
| Q4 25 | $34.6M | $2.9M | ||
| Q3 25 | $-1.1M | $9.4M | ||
| Q2 25 | $18.7M | $787.0K | ||
| Q1 25 | $-24.4M | $8.7M | ||
| Q4 24 | $47.5M | $-10.3M | ||
| Q3 24 | $24.0M | $12.4M | ||
| Q2 24 | $43.6M | $8.5M | ||
| Q1 24 | $-4.6M | $6.6M |
| Q4 25 | 24.8% | 3.1% | ||
| Q3 25 | -0.8% | 10.5% | ||
| Q2 25 | 15.3% | 0.9% | ||
| Q1 25 | -21.2% | 10.1% | ||
| Q4 24 | 40.4% | -10.8% | ||
| Q3 24 | 20.0% | 14.0% | ||
| Q2 24 | 40.7% | 10.0% | ||
| Q1 24 | -5.6% | 7.6% |
| Q4 25 | 0.8% | 0.3% | ||
| Q3 25 | 10.7% | 0.1% | ||
| Q2 25 | 2.0% | 0.2% | ||
| Q1 25 | 4.1% | 0.4% | ||
| Q4 24 | 2.3% | 0.2% | ||
| Q3 24 | 0.9% | 0.1% | ||
| Q2 24 | 1.9% | 0.2% | ||
| Q1 24 | 2.9% | 0.3% |
| Q4 25 | 0.72× | 1.07× | ||
| Q3 25 | 0.36× | 20.96× | ||
| Q2 25 | 0.62× | — | ||
| Q1 25 | -0.73× | — | ||
| Q4 24 | 0.45× | -3.19× | ||
| Q3 24 | 0.70× | — | ||
| Q2 24 | 1.42× | — | ||
| Q1 24 | -0.12× | — |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
ADMA
| ADMA Bio Manufacturing Segment | $123.1M | 88% |
| Other | $16.0M | 12% |
SCOR
| Transferred Over Time | $77.1M | 83% |
| Research Insight Solutions | $14.6M | 16% |
| Related Party | $2.5M | 3% |
